Citations

Clear

941 citation(s) found for "Tefferi, A".

Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencing
Patnaik, Mrinal M. , Finke, Christy M. , Hanson, Curtis A. , King, Rebecca L. , Ketterling, Rhett P. , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Ketterling, Rhett P

Mayo Clinic

American Journal of Hematology | February 14, 2016 | Volume: 91 | Issue: 5 | Pages: 492-498

10.1002/ajh.24332 | PMID 26874914 Get It

Refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) shares overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). RARS‐T is characterized by SF3B1 and JAK2 mutations and prognosis is considered to be better than MDS but not as good as MPN. The objective of the study was to identify predictors of survival in RARS‐T. We analyzed clinical and laboratory variables in 82 patients and applied a 27‐gene NGS assay to 48 marrow samples obtained at diagnosis. 94% of patients had ≥1 mutations; common mutations being: SF3B1 85%, JAK2 V617F 33%, ASXL1 29%, DNMT3A 13%, SETBP1 13% and TET2 10%. In a multivariable survival analysis ( n = 82), anemia ( P = 0.02) [HB< 10 gm/dl: HR 2.3, 95% CI 1.2–4.6] and abnormal karyotype ( P =.01) [HR 6.1, 95% CI 2.7‐13.8] were independently prognostic for inferior survival. In patients with NGS information ( n = 48), univariate analysis showed association between poor survival and presence of SETBP1 ( P = 0.04) or ASXL1 ( P = 0.08) mutations whereas the absence of these mutations ( ASXL1 wt/ SETBP1 wt) was favorable ( P = 0.04); the number of concurrent mutations did not provide additional prognostication ( P = 0.3). We developed a HR‐weighted prognostic model, with 2 points for an abnormal karyotype, 1 point for either ASXL1 and/or SETBP1 mutations, and 1 point for a HB level < 10 gm/dl, which effectively stratified patients into three risk categories; low (0 points), intermediate (1 point) and high (≥2 points), with median survivals of 80, 42 and 11 months respectively ( P = 0.01). In summary, we confirm the unique mutational landscape in RARS‐T and provide a novel mutation‐enhanced prognostic model. Am. J. Hematol. 91:492–498, 2016. © 2016 Wiley Periodicals, Inc.
Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients
Haider, Mahnur , Gangat, Naseema , Hussein, Ahmed Kamel Abou, Elala, Yoseph, Hanson, Curtis A. , Tefferi, Ayalew , Abou Hussein, Ahmed K, Elala, Yoseph C, Hanson, Curtis, Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | January 22, 2016 | Volume: 91 | Issue: 4 | Pages: 390-394

10.1002/ajh.24293 | PMID 26799697 Get It

The primary objective of treatment in essential thrombocythemia (ET) is to prevent thromboembolic complications. In this regard, advanced age and thrombosis history have long distinguished “low” from “high” risk patients. More recently, JAK2V617F and cardiovascular (CV) risk factors were identified as additional modifiers, leading to the development of a 3‐tiered International Prognostic Score of Thrombosis for ET (IPSET‐thrombosis): “low,” “intermediate,” and “high”. The international data set used to develop IPSET‐thrombosis was recently re‐analyzed in order to quantify the additional pro‐thrombotic effect of JAK2V617F and CV risk factors in specific risk subcategories. The revised IPSET‐thrombosis identified four risk categories based on three adverse variables (thrombosis history, age >60 years and JAK2V617F): very low (no adverse features), low (presence of JAK2V617F), intermediate (age >60 years) and high (presence of thrombosis history or presence of both advanced age and JAK2V617F). In this study of 585 patients with ET (median age 68 years; 61% female), we validated the revised IPSET‐thrombosis by confirming significant differences in thrombosis risk between “very low” and “low” (HR 2.4, 95% CI 1.1 − 5.3) and between “intermediate” and “high” (HR 2.3, 95% CI 1.1 − 5.2) risk patients. Furthermore, in multivariable analysis, only JAK2V617F (HR=1.8, CI= 1.07 − 2.94) and history of thrombosis (HR=2.1, CI= 1.20 − 3.58) were independently predictive of future thrombotic events. The revised IPSET‐thrombosis needs confirmation in prospective studies, especially in terms of risk‐adapted therapy that includes the need for aspirin therapy in very low risk, twice‐daily aspirin therapy for low risk and cytoreductive therapy for low or intermediate risk patients. Am. J. Hematol. 91:390–394, 2016. © 2016 Wiley Periodicals, Inc.
Myeloproliferative neoplasms: Morphology and clinical practice
Barbui, Tiziano , Thiele, Jürgen, Tefferi, Ayalew , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | December 31, 2015 | Volume: 91 | Issue: 4 | Pages: 430-433

10.1002/ajh.24288 | PMID 26718907 Get It

In myeloproliferative neoplasms (MPNs), controversy persists regarding the usefulness and reproducibility of bone marrow (BM) features. Disagreements concerning the WHO classification are mainly focused on the discrimination between essential thrombocythemia (ET) and prefibrotic/early primary myelofibrosis (prePMF) and prodromal polycythemia vera (PV). Criticism mostly refers to lack of standardization of distinctive BM features precluding correct morphological pattern recognition. The distinction between WHO‐defined ET and prePMF is not trivial because outcome is significantly worse in prePMF. Morphology was generally considered to be non‐specific for the diagnosis of PV. Recent studies have revealed under‐diagnosis of morphologically and biologically consistent PV. Am. J. Hematol. 91:430–433, 2016. © 2015 Wiley Periodicals, Inc.
Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management
Elliott, Michelle A. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | December 23, 2015 | Volume: 91 | Issue: 3 | Pages: 341-349

10.1002/ajh.24284 | PMID 26700908 Get It

Chronic neutrophilic leukemia (CNL) is a potentially aggressive myeloproliferative neoplasm, for which current WHO diagnostic criteria include leukocytosis of ≥25 × 109/L (of which >80% are neutrophils) and with <10 and <1% circulating immature granulocytes and blasts, respectively without dysplasia, clinical, or molecular criteria for other myeloproliferative disorders, nor an identifiable cause for physiologic neutrophilia in the absence of markers of myeloid clonality. Such a pathogenic clonal marker has now been identified as a somatic activating mutation of CSF3R, most commonly CSF3R T618I, thus demanding revision of the current WHO diagnostic classification to include the molecular criterion of mutated CSF3R. The clinical presentation, disease course and prognosis of CSF‐R mutated CNL have been recently outlined. Co‐operative mutations in SETBP1 and ASXL1 appear to be of prognostic significance and correlate with disease progression. Advances in the understanding of the molecular pathogenesis of CNL, have not yet fully translated into satisfactory therapeutic strategies, but the foundations for these are strengthening. Am. J. Hematol. 91:342–349, 2016. © 2015 Wiley Periodicals, Inc.
Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis
Patnaik, Mrinal M. , Finke, Christy M. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | December 11, 2015 | Volume: 91 | Issue: 3 | Pages: No page available

10.1002/ajh.24267 | PMID 26662677 Get It

Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1‐PDGFRA mutation
Pardanani, Animesh , Barraco, Daniela , Patnaik, Mrinal M. , Elala, Yoseph, Tefferi, Ayalew , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | December 11, 2015 | Volume: 91 | Issue: 3 | Pages: No page available

10.1002/ajh.24273 | PMID 26663400 Get It

ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis
Pardanani, Animesh , Finke, Christy M. , Zblewski, Darci, Abdelrahman, Ramy A., Wassie, Emnet A, Gangat, Naseema , Hanson, Curtis A. , Ketterling, Rhett P. , Tefferi, Ayalew , Pardanani, Animesh D, Lasho, Terra L. , Zblewski, Darci L, Ketterling, Rhett P

Mayo Clinic

British Journal of Haematology | December 2, 2015 | Volume: 175 | Issue: 3 | Pages: 534-536

10.1111/bjh.13865 | PMID 26628266 Get It

Myelodysplastic syndromes: Contemporary review and how we treat
Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | November 24, 2015 | Volume: 91 | Issue: 1 | Pages: 76-89

10.1002/ajh.24253 | PMID 26769228 Get It

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. Diagnosis is currently based on the presence of peripheral blood cytopenias, peripheral blood and bone marrow dysplasia/blasts, and clonal cytogenetic abnormalities. With the advent of next generation sequencing, recurrent somatic mutations in genes involved in epigenetic regulation (TET2, ASXL1, EZH2, DNMT3A, IDH1/2), RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2), DNA damage response (TP53), transcriptional regulation (RUNX1, BCOR, ETV6) and signal transduction (CBL, NRAS, JAK2) have been identified in MDS. Conventional prognostication is by the revised International prognostic scoring system (IPSS‐R) with additional adverse prognosis conferred by presence of ASXL1, EZH2, or TP53 mutations. Currently Food and Drug administration (FDA)‐approved drugs for the treatment of MDS are not curative and their effect on survival is limited; they include the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem cell transplant (ASCT) remains the only treatment option for possible cure. Given the current lack of drugs with convincing evidence of favorable effect on survival, we consider ASCT as the treatment of choice for most patients with symptomatic disease, and especially for those with high‐risk disease. For nontransplant candidates, participation in clinical trials is preferred over conventional therapy. There is not one right way of treatment for patients who are not candidates for either ASCT or clinical trials and palliative drugs of choice depend on the clinical problem, such as symptomatic anemia (ESAs, danazol, HMA), thrombocytopenia (HMA), or neutropenia (myeloid growth factors). Conversely, there is no controlled evidence to support the use of iron chelating agents in MDS. Going forward, we believe it is time to incorporate mutation information in clinically derived prognostic models in MDS and encourage development of novel drugs with disease‐modifying activity. Am. J. Hematol. 91:76–89, 2016. © 2015 Wiley Periodicals, Inc.
Bendamustine therapy associated resolution of anemia and splenomegaly in myelofibrosis
Tefferi, Ayalew , Cerquozzi, Sonia , Liaw, Jenny

Mayo Clinic

American Journal of Hematology | November 20, 2015 | Volume: 91 | Issue: 2 | Pages: No page available

10.1002/ajh.24248 | PMID 26587685 Get It

Myeloproliferative neoplasms: A decade of discoveries and treatment advances
Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | October 22, 2015 | Volume: 91 | Issue: 1 | Pages: 50-58

10.1002/ajh.24221 | PMID 26492355 Get It

Myeloproliferative neoplasms (MPN) are clonal stem cell diseases, first conceptualized in 1951 by William Dameshek, and historically included chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In 1960, Nowell and Hungerford discovered an invariable association between the Philadelphia chromosome (subsequently shown to harbor the causalBCR‐ABL1mutation) and CML; accordingly, the term MPN is primarily reserved for PV, ET, and PMF, although it includes other related clinicopathologic entities, according to the World Health Organization (WHO) classification system. In 2005, William Vainchenker and others described a Janus kinase 2 mutation (JAK2V617F) in MPN and this was followed by a series of additional descriptions of mutations that directly or indirectly activate JAK‐STAT:JAK2exon 12, myeloproliferative leukemia virus oncogene (MPL) and calreticulin (CALR) mutations. The discovery of these, mostly mutually exclusive, “driver” mutations has contributed to revisions of the WHO diagnostic criteria and risk stratification in MPN. Mutations other thanJAK2,CALRandMPLhave also been described in MPN and shown to provide additional prognostic information. From the standpoint of treatment, over the last 50 years, Louis Wasserman from the Unites States and Tiziano Barbui from Italy had skillfully organized and led a number of important clinical trials, whose results form the basis for current treatment strategies in MPN. More recently, allogeneic stem cell transplant, as a potentially curative treatment modality, and JAK inhibitors, as palliative drugs, have been added to the overall therapeutic armamentarium in myelofibrosis. In the current review, I will summarize the important advances made in the last 10 years regarding the science and practice of MPN. Am. J. Hematol. 91:50–58, 2016. © 2015 Wiley Periodicals, Inc.